Summary
Andrew Fleury is a Managing Director and CEO based in Chiyoda, Japan, specializing in Japan market entry for foreign biotechs, with deep expertise in cell and gene therapies, regenerative medicine, and Japanese pharmaceutical regulations. Over eight years he has led strategic, regulatory, financial partnering and clinical operations work—helping foreign developers negotiate licensing, identify manufacturing and marketing partners, and advising Japanese pharma on due diligence and in-licensing. He founded and scaled projects at CJ PARTNERS, built therapy databases tracking vectors/cell types and global development, and has served on a biotech supervisory board. Comfortable bridging Western companies and Japanese stakeholders, he combines language and cultural fluency with hands-on deal execution and regulatory navigation. His background in economics and East Asian studies alongside early career roles in business development and operations gives him a rare mix of commercial, regulatory, and academic insight. Known for translating complex scientific and regulatory detail into actionable commercial strategy, he repeatedly opens Japan as a practical, fundable market for advanced therapies.
7 years of coding experience
8 years of employment as a software developer
Japanese Language and Literature, Japanese Language and Literature at Inter-University Center for Japanese Language Studies (IUC)
B.A., Economics, Asian Studies, B.A., Economics, Asian Studies at Cornell University
M.A., East Asian Studies (Japan), M.A., East Asian Studies (Japan) at Stanford University
English, Japanese, Spanish